Desmopressin (DDAVP) is a vasopressin peptide analog with hemostatic properties that has been successfully used during surgery in patients with bleeding disorders. Recently published experimental and clinical data indicate that perioperative administration of DDAVP can minimize spread and survival of residual mammary cancer cells. The central aim of this study was to explore the effect of perioperative DDAVP and its relation to histologic grade in bitches with locally-advanced mammary carcinoma. Of the 32 dogs initially recruited, 28 intact bitches with mammary carcinoma tumors stage III or IV were ultimately included. These dogs were Q:4 randomized to receive DDAVP at intravenous doses of 1 mg/kg (n¼18) or saline solution as placebo (n¼10). En bloc mastectomy of the affected gland(s) was performed. Tumor malignancy was graded by the method of Elston and Ellis into well-differentiated (grade 1), moderately differentiated (grade 2), or poorly differentiated (grade 3).
Introduction
Mammary tumors are the most frequent neoplasm in female dogs. 1, 2 Occurrence of malignant forms varies from 40% to 50%
with carcinoma being the most common histopathological type. 2, 3 The treatment of choice of mammary tumors is surgical excision;
however, surgery alone does not provide a cure in advanced or aggressive cancers. 4 The outcome of postoperative chemotherapy is uncertain in canine mammary cancer and its effect on survival has not been clearly documented. [5] [6] [7] [8] Candidates for adjuvant therapy are dogs with locally-advanced disease, including primary tumors .5 cm in maximum diameter (clinical stage III), and tumors of any size with loco-regional lymph node involvement (clinical stage IV). 9 Dogs with aggressive cancers (i.e., those with a high histologic grade) are also good candidates for adjuvancy. In this regard, histologic grading of canine mammary carcinomas is strongly related to prognosis and its routine use appears to be helpful in suggesting appropriate adjuvant therapy. 10 In a pilot study, desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) prolonged survival in bitches with mammary cancer when administered during surgical excision of the primary tumor. 11 In addition, DDAVP inhibited lymph node and lung metastasis in murine models of mammary cancer. 12, 13 DDAVP is a synthetic peptide compound with hemostatic properties that has been used in humans and dogs with diabetes insipidus and von
Willebrand disease. [14] [15] [16] DDAVP is a safe and effective hemostatic agent for use during surgery in patients with bleeding disorders. 
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The compound increases plasma levels of coagulation factor VIII, von Willebrand factor (VWF) and tissue-type plasminogen activator. 17, 18 Taking into account the pilot study on the antimetastatic properties of DDAVP and its well known effect on hemostasis, our research group conducted an extended study including a larger number of bitches. The central aim was to investigate the effect of perioperative DDAVP and its relation to histologic grade in bitches with locally-advanced mammary carcinoma.
Materials and Methods

Animals
Between September 2003 and January 2008, 32 purebreed and mixed-breed otherwise healthy intact bitches, 5-13 yr old, and weighing 4-55 kg with stage III or IV mammary carcinoma (confirmed by deferred biopsy) were included in the study. 9 Metastases were ruled out by lateral and ventrodorsal thoracic radiographs.
General health was confirmed by routine complete blood cell counts, blood biochemistry, and coagulation tests. 19, 20 A wide surgical margin of at least 3 cm around the tumor was performed in all cases. Skin margins were checked by histopathology in some cases and regional lymph nodes were excised in all cases.
Histopathology and Grading of Mammary Carcinoma
Representative fragments of each mammary tumor and the excised lymph nodes were fixed in 10% formalin, embedded in paraffin, sectioned at 5 mm, and stained with hematoxylin and eosin using routine procedures. Histopathological findings were recorded by a specialized pathologist and tumors were classified according to Misdorp et al. (1999) . 21 In cases with multiple tumors, the highergrade malignant lesion was recorded.
Tumor malignancy was graded histologically by the method 
Follow-up
Clinical evaluation including general health, remaining mammary glands and lymph nodes, surgical scarring, and side effects were performed whenever there appeared to be any change in the patient or every 3 mo for a minimum of 12 mo postsurgically. Thoracic metastases were either diagnosed or ruled out by lateral and ventrodorsal radiographs at the time of each evaluation. Euthanasia was performed only in the terminal stage of disease and no post mortem examinations were performed.
Statistical Analysis
Median (range) and number (percent) were calculated where appropriate. Overall and disease-free survival were defined as the time from surgery to death or recurrence (local, regional, or distant), respectively. Animals were statistically censored if their tumor had not recurred or no distant metastases had been detected at the time of death or data accrual closure. In the survival analysis, animals were statistically censored if they were alive at the time of data accrual closure. Survival probability curves were estimated using the Kaplan-Meier method and treatment groups were compared by the log-rank test using the GraphPad Prism software h . 26 To verify the comparability of the treatment groups, 
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Results
Treatment groups presented similar findings with regard to dog age and weight, size, and number of tumor lesions, clinical stage, and histopathological features of mammary carcinoma ( Table 1) .
The most frequently diagnosed tumor type was simple carcinoma (n¼22). Other diagnosed types included complex carcinoma (n¼2), squamous cell carcinoma (n¼1), lipid-rich carcinoma (n¼1), carcinosarcoma (n¼1), and anaplastic carcinoma (n¼1).
The different histologic grades were represented in both groups, although moderately differentiated (grade 2) tumors were the most frequent in the placebo group and poorly differentiated (grade 3)
tumors were the most frequent in the DDAVP group. Four cases were diagnosed as having noncarcinoma lesions, including two cases with osteosarcoma, one case with a mixed benign tumor in the DDAVP group, and one case with lobular hyperplasia and adenosis in the placebo group. These four cases were therefore excluded from the study. Uni-and multivariate logistic regression revealed that none of the analyzed variables significantly influenced disease-free and overall survival. DDAVP was well tolerated at the dose used in the study and overt toxic effects were not Q:1 documented in any of the included cases.
Independent of the histologic grade, five (28%) and eight (80%) patients in the DDAVP and placebo groups, respectively, presented either local relapses or lung metastasis during the study period ( Table 2) . Kaplan-Meier analysis indicated that DDAVP had a positive effect on median disease-free survival. Median disease-free survival was 608 days in the DDAVP group versus 88 days in the placebo group (P,0.001) ( Figure 1A) . Three (17%) and eight (80%) cases in the DDAVP and placebo groups, respectively, died during the study period. Median overall survival was 809 days in the DDAVP and only 237 days in the placebo group (P,0.01) ( Figure 1B ). Figures 2A and B 
As shown in
Discussion
The present work confirmed the beneficial effect of perioperative DDAVP on disease-free and overall survival in bitches with locallyadvanced mammary carcinoma, as suggested by a previously reported pilot study. 11 The compound was administered as a surgical adju- In such a model, perioperative administration of DDAVP decreased metastatic foci by 70%. 13 In the present canine study, DDAVP did not eliminated residual tumors in all cases; however, only 28% of animals receiving perioperative treatment developed a late local relapse or lung metastasis whereas most bitches in the placebo group experienced a rapid disease progression. DDAVP seemed to improve perioperative hemostasis and may have contributed to a rapid encapsulation of residual tumor tissue limiting extravasation of metastatic cells. 11 In this regard, intravenous DDAVP prevented aggregation of mammary carcinoma cells thereby reducing the efficiency of the metastatic process. 12 It is known that the IVadministration of DDAVP induces a rapid release of highly multimeric forms of VWF from microvascular 28 Together, these observations suggest that abrupt release of VWF from the microvasculature may favor the collapse of early metastatic foci. Thus, it is likely that DDAVP injection not only inhibits perioperative metastatic events but also combats spontaneous micrometastases that occurred before surgery.
In addition, DDAVP is a selective agonist for the vasopressin V2 membrane receptor that is expressed in endothelial cells and also in several tumor variants, including mammary cancer. 29 A mild antiproliferative effect of DDAVP was previously reported on mammary carcinoma cell lines. 30, 31 Such action is likely to be mediated through V2 receptor signaling and involves activation of adenylate cyclase followed by intracellular cyclic adenosine monophosphate elevation. 31 Other authors have shown that the natural hormone vasopressin can inhibit the in vitro growth of MCF-7 human breast carcinoma cells at high concentrations. 32 Histologic grading of canine mammary carcinomas was significantly related to prognosis, especially in cases of simple carcinoma. 9 The improved method of Elston and Ellis for histologic grading of carcinoma provides powerful prognostic information. The measurement of three parameters (i.e., tubule formation, nuclear pleomorphism, and mitotic count) markedly reduced problems of consistency and reproducibility. 22 In the current study, adjuvant perioperative treatment with DDAVP prolonged survival in bitches with moderately-or poorlydifferentiated (grade 2 or 3, respectively) carcinomas. The effect was not significant in bitches with well-differentiated (grade 1)
carcinomas. These observations indicate that perioperative DDAVP can provide a beneficial effect in patients with aggressive disease at high risk of recurrence or metastasis. for grade 3 carcinomas (log-rank test).
